Last reviewed · How we verify
An Open-label, Single-dose Study to Assess the Pharmacokinetics of Imrecoxib in Subjects With Impaired Hepatic Function
This clinical research study will assess pharmacokinetics and the safety of Imrecoxib in patients with impaired hepatic function as compared to healthy volunteers.
Details
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | 2015-01 |
| Completion | 2015-07 |
Conditions
- Knee Osteoarthritis
Interventions
- Imrecoxib
Primary outcomes
- Area under the concentration time curve from 0 to infinity (AUC0-∞) after a single — First 5 days
- Maximum observed plasma drug concentration (Cmax) after a single oral dose of — First 5 days
- Time to maximum observed plasma drug concentration (Tmax) after a single oral dose of Imrecoxib. — First 5 days
Countries
China